Staged IOL implantation = happy patients

Article

By employing staged implantation of intraocular lenses (IOLs), surgeons can produce the best possible visual outcomes for each individual patient.

By employing staged implantation of intraocular lenses (IOLs), surgeons can produce the best possible visual outcomes for each individual patient, according to Richard Lindstrom from Minnesota, USA.

Dr Lindstrom conducted a case series in which 23 patients received a dual diffractive IOL combination (ReStor/ReStor; Alcon) and 29 patients were implanted with a diffractive/refractive IOL combination (ReStor/ReZoom; AMO), using the process of staged implantation.

It was discovered that patient satisfaction with distance vision improved from 74% with the dual diffractive IOLs to 96% with the diffractive/refractive combination. Satisfaction with near vision improved from 83% to 96% and willingness to recommend the procedure to others improved from 64% to 96%. Furthermore, subjects with the diffractive/refractive combination reported spectacle independence 94% of the time, compared with just 65% of the time for the subjects with the dual diffractive IOLs.

Dr Lindstrom believes that the staged process can provide the best possible visual outcomes and that combining two different types of refractive IOLs leads to high levels of spectacle independence and patient satisfaction.

Recent Videos
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
© 2024 MJH Life Sciences

All rights reserved.